Patents by Inventor Takashi Kei Kishimoto

Takashi Kei Kishimoto has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • VIRAL VECTOR DOSING PROTOCOLS
    Publication number: 20240024517
    Abstract: Disclosed, at least in part, are dosings of viral vectors concomitantly with synthetic nanocarriers attached to an immunosuppressant, in combination with dosings of the synthetic nanocarriers attached to an immunosuppressant without a viral vector or dosings of the synthetic nanocarriers attached to an immunosuppressant concomitantly with lower doses of the viral vector, and related compositions that provide reduced humoral immune responses and/or increased or durable transgene or nucleic acid material expression.
    Type: Application
    Filed: June 28, 2023
    Publication date: January 25, 2024
    Inventor: Takashi Kei Kishimoto
  • HIGH AFFINITY IL-2 RECEPTOR AGONISTS AND IMMUNOSUPPRESSANTS TO ENHANCE IMMUNE TOLERANCE
    Publication number: 20230381277
    Abstract: Disclosed are methods and related compositions for administering a high affinity IL-2 receptor agonist in combination with immunosuppressants. The methods and compositions provided can be used for enhancing regulatory T cells, including antigen-specific regulatory T cells.
    Type: Application
    Filed: April 7, 2023
    Publication date: November 30, 2023
    Inventors: Takashi Kei Kishimoto, Petr Ilyinskii
  • SYNTHETIC NANOCARRIERS COMPRISING AN IMMUNOSUPPRESSANT IN COMBINATION WITH HIGH AFFINITY IL-2 RECEPTOR AGONISTS AND ANTI-IGM AGENTS
    Publication number: 20230372535
    Abstract: Disclosed are methods and related compositions for administering a high affinity IL-2 receptor agonist, an anti-IgM agent and immunosuppressant (e.g., synthetic nanocarriers comprising immunosuppressant) in combination. The methods and compositions provided can be used for modulating an immune response to an antigen, such as by enhancing regulatory T cells, such as antigen-specific regulatory T cells.
    Type: Application
    Filed: March 24, 2023
    Publication date: November 23, 2023
    Applicant: Selecta Biosciences, Inc.
    Inventor: Takashi Kei Kishimoto
  • METHODS AND COMPOSITIONS FOR ATTENUATING ANTI-VIRAL TRANSFER VECTOR IMMUNE RESPONSES
    Publication number: 20230364124
    Abstract: Provided herein are methods and related compositions for administering viral transfer vectors and antigen-presenting cell targeted immunosuppressants.
    Type: Application
    Filed: March 17, 2023
    Publication date: November 16, 2023
    Applicant: Selecta Biosciences, Inc.
    Inventor: Takashi Kei Kishimoto
  • IMMUNOSUPPRESSANTS IN COMBINATION WITH ANTI-IGM AGENTS AND RELATED DOSING
    Publication number: 20230357437
    Abstract: Provided herein are methods and related compositions or kits for administering viral transfer vectors in combination with an immunosuppressant and an anti-IgM agent.
    Type: Application
    Filed: March 8, 2023
    Publication date: November 9, 2023
    Inventors: Petr Ilyinskii, Takashi Kei Kishimoto
  • TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE ANTIBODY RESPONSES
    Publication number: 20230321224
    Abstract: Disclosed are synthetic nanocarrier compositions, and related methods, comprising MHC Class II-restricted epitopes and immunosuppressants that provide tolerogenic immune responses, such as a reduction in CD4+ T cell help specific to an antigen.
    Type: Application
    Filed: December 8, 2022
    Publication date: October 12, 2023
    Applicant: Selecta Biosciences, Inc.
    Inventors: Christopher Fraser, Takashi Kei Kishimoto, Roberto A. Maldonado
  • TOLEROGENIC SYNTHETIC NANOCARRIERS TO REDUCE IMMUNE RESPONSES TO THERAPEUTIC PROTEINS
    Publication number: 20230321225
    Abstract: Disclosed are synthetic nanocarrier compositions, and related methods, comprising therapeutic protein APC presentable antigens and immunosuppressants that provide tolerogenic immune responses specific to therapeutic proteins.
    Type: Application
    Filed: March 2, 2023
    Publication date: October 12, 2023
    Applicant: Selecta Biosciences, Inc.
    Inventors: Christopher Fraser, Takashi Kei Kishimoto, Roberto A. Maldonado
  • IMMUNOSUPPRESSANT IN COMBINATION WITH HIGH AFFINITY IL-2 RECEPTOR AGONISTS AND RELATED DOSING
    Publication number: 20230322884
    Abstract: Disclosed are methods and related compositions for administering a high affinity IL-2 receptor agonist in combination with immunosuppressants. The methods and compositions provided can be used for modulating an immune response to an antigen, such as by enhancing regulatory T cells, such as antigen-specific regulatory T cells.
    Type: Application
    Filed: March 8, 2023
    Publication date: October 12, 2023
    Inventors: Takashi Kei Kishimoto, Petr Ilyinskii
  • Tolerogenic synthetic nanocarriers for allergy therapy
    Patent number: 11779641
    Abstract: Disclosed are synthetic nanocarrier compositions, and related methods, comprising immunosuppressants and MHC Class II-restricted epitopes of an allergen that provide tolerogenic immune responses specific to the allergen.
    Type: Grant
    Filed: March 4, 2016
    Date of Patent: October 10, 2023
    Assignee: Selecta Biosciences, Inc.
    Inventors: Takashi Kei Kishimoto, Christopher Fraser, Roberto A. Maldonado
  • TOLEROGENIC SYNTHETIC NANOCARRIERS FOR ALLERGY THERAPY
    Publication number: 20230310593
    Abstract: Disclosed are synthetic nanocarrier compositions, and related methods, comprising immunosuppressants and MHC Class II-restricted epitopes of an allergen that provide tolerogenic immune responses specific to the allergen.
    Type: Application
    Filed: December 9, 2022
    Publication date: October 5, 2023
    Applicant: Selecta Biosciences, Inc.
    Inventors: Takashi Kei Kishimoto, Christopher Fraser, Roberto A. Maldonado
  • HIGH AFFINITY IL-2 RECEPTOR AGONISTS AND SYNTHETIC NANOCARRIER DOSE SPARING
    Publication number: 20230263906
    Abstract: Disclosed are methods and related compositions for administering a high affinity IL-2 receptor agonist in combination with immunosuppressants (e.g., comprised in synthetic nanocarriers), wherein the immunosuppressant is at a reduced effective dose.
    Type: Application
    Filed: January 9, 2023
    Publication date: August 24, 2023
    Inventor: Takashi Kei Kishimoto
  • METHODS AND COMPOSITIONS FOR ATTENUATING ANTI-VIRAL TRANSFER VECTOR IGM RESPONSES
    Publication number: 20230141563
    Abstract: Provided herein are methods and related compositions or kits for administering viral transfer vectors in combination with synthetic nanocarriers comprising an immunosuppressant and an anti-IgM agent.
    Type: Application
    Filed: October 12, 2022
    Publication date: May 11, 2023
    Inventors: Petr Ilyinskii, Takashi Kei Kishimoto
  • METHODS AND COMPOSITIONS FOR INDUCING AUTOPHAGY
    Publication number: 20230147052
    Abstract: Provided herein are methods and compositions related to compositions comprising synthetic nanocarriers comprising an immunosuppressant. Also provided herein are methods and compositions for inducing or increasing autophagy.
    Type: Application
    Filed: April 14, 2020
    Publication date: May 11, 2023
    Inventors: Petr Ilyinskii, Takashi Kei Kishimoto
  • VIRAL VECTOR DOSING PROTOCOLS
    Publication number: 20230140196
    Abstract: Disclosed, at least in part, are dosings of viral vectors concomitantly with synthetic nanocarriers attached to an immunosuppressant, in combination with dosings of the synthetic nanocarriers attached to an immunosuppressant without a viral vector or further dosings of the synthetic nanocarriers attached to an immunosuppressant concomitantly with doses of the viral vector, and related compositions that provide reduced humoral immune responses and/or increased or durable transgene or nucleic acid material expression.
    Type: Application
    Filed: October 12, 2022
    Publication date: May 4, 2023
    Inventor: Takashi Kei Kishimoto
  • Methods and compositions for attenuating anti-viral transfer vector immune responses
    Patent number: 11633422
    Abstract: Provided herein are methods and related compositions for administering viral transfer vectors and antigen-presenting cell targeted immunosuppressants.
    Type: Grant
    Filed: September 7, 2015
    Date of Patent: April 25, 2023
    Assignee: Selecta Biosciences, Inc.
    Inventor: Takashi Kei Kishimoto
  • SYNTHETIC NANOCARRIERS COMPRISING AN IMMUNOSUPPRESSANT IN COMBINATION WITH HIGH AFFINITY IL-2 RECEPTOR AGONISTS TO ENHANCE IMMUNE TOLERANCE
    Publication number: 20220323607
    Abstract: Disclosed are methods and related compositions for administering a high affinity IL-2 receptor agonist in combination with immunosuppressants. The methods and compositions provided can be used for enhancing regulatory T cells, including antigen-specific regulatory T cells.
    Type: Application
    Filed: April 8, 2022
    Publication date: October 13, 2022
    Applicant: Selecta Biosciences, Inc.
    Inventors: Takashi Kei Kishimoto, Petr Ilyinskii
  • METHODS AND COMPOSITIONS FOR REDUCING IMMUNE RESPONSES AGAINST IMMUNOGLOBULIN PROTEASES
    Publication number: 20220133864
    Abstract: Disclosed are methods and related compositions for administering an immunoglobulin (Ig) protease in combination with synthetic nanocarriers comprising immunosuppressants. The methods and compositions provided can be used for treating Ig deposition diseases and disorders, such as IgA nephropathy.
    Type: Application
    Filed: November 4, 2021
    Publication date: May 5, 2022
    Inventor: Takashi Kei Kishimoto
  • METHODS OF ADMINISTERING IMMUNOSUPPRESSANTS HAVING A SPECIFIED PHARMACODYNAMIC EFFECTIVE LIFE AND THERAPEUTIC MACROMOLECULES FOR THE INDUCTION OF IMMUNE TOLERANCE
    Publication number: 20220071968
    Abstract: This invention relates to methods that provide immunosuppressants and therapeutic macromolecules that are administered within a pharmacodynamically effective window of the immunosuppressants to induce immune tolerance to the therapeutic macromolecules. The methods allow shifting the immune response in favor of tolerogenic immune response development specific to the therapeutic macromolecule.
    Type: Application
    Filed: March 24, 2021
    Publication date: March 10, 2022
    Applicant: Selecta Biosciences, Inc.
    Inventor: Takashi Kei Kishimoto
  • METHODS AND COMPOSITIONS USING SYNTHETIC NANOCARRIERS COMPRISING IMMUNOSUPPRESSANT
    Publication number: 20210290601
    Abstract: Provided herein are methods and compositions related to synthetic nanocarriers comprising an immunosuppressant that can be used, for example, for inducing autophagy and/or promoting a tolerogenic phenotype.
    Type: Application
    Filed: February 26, 2021
    Publication date: September 23, 2021
    Applicant: Selecta Biosciences, Inc.
    Inventors: Petr Ilyinskii, Takashi Kei Kishimoto
  • FORMULATIONS AND DOSES OF PEGYLATED URICASE
    Publication number: 20210187081
    Abstract: Provided herein are methods and compositions related to the administration of uricase compositions and compositions comprising synthetic nanocarriers comprising an immunosuppressant for the treatment of subjects, including subjects with hyperuricemia, gout or a condition associated with gout.
    Type: Application
    Filed: November 6, 2020
    Publication date: June 24, 2021
    Applicant: Selecta Biosciences, Inc.
    Inventors: Lloyd Johnston, Takashi Kei Kishimoto, Earl Sands, Werner Cautreels